Literature DB >> 9811235

Comparison of fluconazole pharmacokinetics in serum, aqueous humor, vitreous humor, and cerebrospinal fluid following a single dose and at steady state.

U K Mian1, M Mayers, Y Garg, Q F Liu, G Newcomer, C Madu, W Liu, A Louie, M H Miller.   

Abstract

The objective of this study was to characterize the pharmacokinetic parameters and penetration of fluconazole following a single dose in the serum, aqueous humor, vitreous humor and cerebrospinal fluid (CSF) of non pigmented rabbits using serial sampling techniques and to determine if the pharmacokinetic parameters in the eye and CSF are similar. Twenty healthy male rabbits received intravenous fluconazole 20 mg/kg as a single dose or 20 mg/kg every 12 hours for 4 doses. Serum, aqueous humor, vitreous humor and CSF samples were taken 15 minutes after the initial intravenous injection and hourly thereafter for six hours. Fluconazole concentrations were determined by microbiological assay. Pharmacokinetic analyses were performed using a nonlinear least-square regression program. Fluconazole's penetration in all anatomical compartments was > 70% than in the serum. Similar elimination half-lives and time to reach maximum concentrations were noted in all compartments. While mean concentrations in each anatomical compartment were similar in animals receiving a single dose or among those at serum steady state, the mean concentrations achieved in the serum, aqueous and vitreous humors and CSF were between 1.82 and 2.17 times higher at serum steady state than following a single dose. At serum concentrations that are comparable to those in humans, the penetration of fluconazole into the noninflamed aqueous and vitreous humors and CSF were > or = 70%. The CSF and ocular pharmacokinetic parameters closely resembled each other, so that either could be used as a surrogate for the other.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811235     DOI: 10.1089/jop.1998.14.459

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  6 in total

1.  Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.

Authors:  A Louie; W Liu; D A Miller; A C Sucke; Q F Liu; G L Drusano; M Mayers; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

2.  Effects of immunomodulatory and organism-associated molecules on the permeability of an in vitro blood-brain barrier model to amphotericin B and fluconazole.

Authors:  Vasilios Pyrgos; Diane Mickiene; Tin Sein; Margaret Cotton; Andrea Fransesconi; Isaac Mizrahi; Martha Donoghue; Nikkida Bundrant; Su-Young Kim; Matthew Hardwick; Shmuel Shoham; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

Review 3.  Fluconazole pharmacokinetics and safety in premature infants.

Authors:  K Turner; P Manzoni; D K Benjamin; M Cohen-Wolkowiez; P B Smith; M M Laughon
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

4.  Acanthamoeba endophthalmitis during treatment for cutaneous disease in a renal transplant patient.

Authors:  Allison Kutner; Margaret Aldrich; Sarju Patel; Joann J Kang; Bijal Amin; Ranon Mann; Ibne Karim M Ali; Roosecelis Brasil Martines; Jennifer Rittenhouse Cope; Graciela O De Boccardo; Yoram A Puius
Journal:  Transpl Infect Dis       Date:  2018-02-12       Impact factor: 2.228

Review 5.  Current perspectives on ophthalmic mycoses.

Authors:  Philip A Thomas
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

6.  Fungicidal activity of fluconazole against Candida albicans in a synthetic vagina-simulative medium.

Authors:  Mahomed-Yunus S Moosa; Jack D Sobel; Hussain Elhalis; Wenjin Du; Robert A Akins
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.